- Zacks•13 hours ago
Glaxo (GSK) reported third-quarter 2016 core earnings of 85 cents per American depositary share, beating the Zacks Consensus Estimate of 77 cents.
- Reuters•15 hours ago
GlaxoSmithKline said on Thursday it was investing 172 million euros ($188 million) to expand vaccine capacity at its Marburg factory in Germany, with 162 million euros going to increase production of its Bexsero meningitis B shot. The British drugmaker highlighted the vaccine's strong sales performance when it reported results on Wednesday, with sales of the product more than doubling in the third quarter to 133 million pounds ($163 million). The company said it would take a number of years for the new production to come on stream but the investment was a vote of confidence in GSK's vaccines business, which was a bright spot in quarterly results.
GlaxoSmithKline plc (GLAXF)
Other OTC - Other OTC Delayed Price. Currency in USD
|Day's Range||19.60 - 19.60|
|52wk Range||19.55 - 21.99|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||261.33|
|Avg Vol (3m)||3,103|
|Dividend & Yield||0.94 (4.75%)|